The new, negative 2.5% efficiency adjustment will be applied to the vast majority of Medicare payments for physician services. It was opposed by cardiology and most other medical societies. 

Electrophysiologists can now perform cardiac ablation outside of a hospital setting. Groups such as the American College of Cardiology and Heart Rhythm Society have been pushing for this change for quite some time, pointing to the potential to cut costs and boost patient satisfaction.

Noninvasive coronary CT angiography is growing more and more important as time goes on, helping cardiologists make critical treatment decisions. Carlos Collet, MD, PhD, discussed the technique's potential to be a real game-changer for patient care in a new interview. 

The new drug from Merck was linked to several benefits for patients who are already on statins. If an oral PCSK9 inhibitor gains FDA approval, it could be a game-changer for the field of preventive medicine. 

The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.

The shunt device being reviewed showed a 52% reduction in hospitalizations and favorable trends in mortality in patients with heart failure with reduced ejection fraction. 

BeamO combines electrocardiogram sensors, a stethoscope and a thermometer into a single device that patients can use at home to learn more about their health. Findings can then be submitted for a cardiologist to review.

First-in-human data suggest the therapy, CTX310, could be a breakthrough for patients with lipid disorders.

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

The WVU Heart and Vascular Institute is hosting a two-day symposium focused on exploring the benefits and long-term potential of robotic aortic valve replacement. Fans of the procedure say it represents a safe, effective alternative to TAVR and SAVR in patients with severe aortic stenosis.